Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 2021Website:
http://www.senseibio.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 118 min agoDividend
Analysts recommendations
Institutional Ownership
SNSE Latest News
Sensei Biotherapeutics (NASDAQ: SNSE ) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA.
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.
What type of business is Sensei Biotherapeutics?
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
What sector is Sensei Biotherapeutics in?
Sensei Biotherapeutics is in the Healthcare sector
What industry is Sensei Biotherapeutics in?
Sensei Biotherapeutics is in the Biotechnology industry
What country is Sensei Biotherapeutics from?
Sensei Biotherapeutics is headquartered in United States
When did Sensei Biotherapeutics go public?
Sensei Biotherapeutics initial public offering (IPO) was on 04 February 2021
What is Sensei Biotherapeutics website?
https://www.senseibio.com
Is Sensei Biotherapeutics in the S&P 500?
No, Sensei Biotherapeutics is not included in the S&P 500 index
Is Sensei Biotherapeutics in the NASDAQ 100?
No, Sensei Biotherapeutics is not included in the NASDAQ 100 index
Is Sensei Biotherapeutics in the Dow Jones?
No, Sensei Biotherapeutics is not included in the Dow Jones index
When does Sensei Biotherapeutics report earnings?
The next expected earnings date for Sensei Biotherapeutics is 02 August 2024